CHANG NANCY T 4

What Happened

• Nancy T. Chang, a director of Immix Biopharma (IMMX), received two equity awards on May 22, 2026: 6,250 restricted stock units (RSUs) and rights to 12,500 derivative shares (a stock‑based award). Both were granted at $0.00, so no cash was paid. These are compensation awards (not open‑market purchases or sales).

Key Details

• Transaction date: May 22, 2026; Filing date: May 29, 2026 (filed after the typical two‑business‑day Form 4 window).
• 6,250 RSUs granted at $0.00. Vesting: vests in full on the earlier of (i) one year after grant or (ii) the issuer's 2027 annual meeting, subject to continued service (Footnote F1).
• 12,500 derivative award (stock option/right) granted at $0.00. Vesting: generally vests in substantially equal monthly installments over 12 months, with any remaining unvested portion vesting if the 2027 annual meeting occurs before the one‑year anniversary, subject to continued board service (Footnote F3).
• Shares owned after the transaction: not specified in the provided Form 4 data.
• Beneficial‑ownership note: Chang is general manager of Robinhood II, LP and may be deemed to beneficially own securities held by that entity, but she disclaims beneficial ownership except to the extent of her pecuniary interest (Footnote F2).
• Remarks: Exhibit 24.1 (Powers of Attorney) included on the filing.

Context

• These awards are typical director compensation and represent future potential equity if vesting conditions are met; they are not sales or purchases indicating immediate market action. RSUs convert to shares at vesting; the derivative award will vest over time and would require exercise/settlement steps before Chang holds shares outright. The Form 4 was filed days after the transaction, which is later than the usual two‑business‑day requirement.